Rhythm Pharmaceuticals (RYTM) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RYTM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rhythm Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$97.61 |
| 52 Week High | US$99.04 |
| 52 Week Low | US$43.57 |
| Beta | 2.39 |
| 1 Month Change | 6.75% |
| 3 Month Change | 62.87% |
| 1 Year Change | 111.83% |
| 3 Year Change | 292.01% |
| 5 Year Change | 428.48% |
| Change since IPO | 225.37% |
Recent News & Updates
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market
Jul 10Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%
Jul 10
Recent updates
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market
Jul 10Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%
Jul 10Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?
Jun 25
Label Expansion And Global Healthcare Will Widen Future Market Opportunities
Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up
May 04Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Apr 08Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Feb 25Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 19Rhythm Pharmaceuticals: A Key Year Ahead
Dec 06Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals: Action Too Specific
Feb 23Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Shareholder Returns
| RYTM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.1% | 4.5% | 1.0% |
| 1Y | 111.8% | -5.1% | 17.1% |
Return vs Industry: RYTM exceeded the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: RYTM exceeded the US Market which returned 17.4% over the past year.
Price Volatility
| RYTM volatility | |
|---|---|
| RYTM Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RYTM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RYTM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 283 | David Meeker | rhythmtx.com |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
Rhythm Pharmaceuticals, Inc. Fundamentals Summary
| RYTM fundamental statistics | |
|---|---|
| Market cap | US$6.41b |
| Earnings (TTM) | -US$188.44m |
| Revenue (TTM) | US$156.29m |
Is RYTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYTM income statement (TTM) | |
|---|---|
| Revenue | US$156.29m |
| Cost of Revenue | US$16.81m |
| Gross Profit | US$139.48m |
| Other Expenses | US$327.92m |
| Earnings | -US$188.44m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 89.25% |
| Net Profit Margin | -120.57% |
| Debt/Equity Ratio | 82.2% |
How did RYTM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/15 11:41 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rhythm Pharmaceuticals, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Jonathan Wolleben | Citizens JMP Securities, LLC |